Search Results - Martin JS Dyer

  • Showing 1 - 3 results of 3
Refine Results
  1. 1

    Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia by Raji E Joseph, Thomas E Wales, Sandrine Jayne, Robert G Britton, D Bruce Fulton, John R Engen, Martin JS Dyer, Amy H Andreotti

    Published in eLife (2024-12-01)
    Get full text
    Article


  2. 2

    The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy by Meike Vogler, Yannick Braun, Victoria M. Smith, Mike-Andrew Westhoff, Raquel S. Pereira, Nadja M. Pieper, Marius Anders, Manon Callens, Tim Vervliet, Maha Abbas, Salvador Macip, Ralf Schmid, Geert Bultynck, Martin JS Dyer

    Published in Signal Transduction and Targeted Therapy (2025-03-01)
    Get full text
    Article


  3. 3

    A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previous... by Marek Trnĕný, Gregor Verhoef, Martin JS Dyer, Dina Ben Yehuda, Caterina Patti, Miguel Canales, Andrés Lopez, Farrukh T Awan, Paul G Montgomery, Andrea Janikova, Anna M Barbui, Kazimierz Sulek, Maria J Terol, John Radford, Anna Guidetti, Massimo Di Nicola, Laure Siraudin, Laurence Hatteville, Sandrine Schwab, Corina Oprea, Alessandro M Gianni

    Published in Haematologica (2018-08-01)
    Get full text
    Article


Search Tools: